JUST IN: The Covid-19 vaccine is safe and shows 'robust' antibody response for 5- to 11-year-olds, Pfizer says
In a highly anticipated announcement, Pfizer said on Monday a Phase 2/3 trial showed its Covid-19 vaccine was safe and generated a"robust" antibody response in children ages 5 to 11.
These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon.The trial included 2,268 participants ages 5 to 11 and used a two-dose regimen of the vaccine administered 21 days apart. This trials used a 10-microgram dose -- smaller than the 30-microgram dose that has been used for those 12 and older.
Coronavirus infections have risen"exponentially" among children across the United States, and now account for nearly 29% of all cases reported nationwide, the American Academy of Pediatrics reported last week. Still, US health officials have emphasized that children are not just small adults, and even those approaching age 12 should not be given the larger vaccine dose available for older people. "We don't want children to have adverse effects.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Pfizer says COVID-19 vaccine safe, effective for kids ages 5 to 11Pfizer and BioNTech released data saying its vaccine is safe and effective for kids 5-11.
Baca lebih lajut »
Pfizer says COVID-19 vaccine works in kids ages 5 to 11Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon -- a key step toward beginning vaccinations for youngsters. The vaccine made by Pfizer and its German partner BioNTech already is available for anyone 12 and older.
Baca lebih lajut »
Pfizer and BioNTech say COVID-19 vaccine safe and effective in children aged 5 to 11Pfizer Inc. undefined and German partner BioNTech SE undefined on Monday announced positive results in a Phase 2/3 trial of their COVID-19 vaccine in...
Baca lebih lajut »
Long Covid Affecting One Third Of People After Covid-19 Coronavirus Infection, CDC MMWR Study FindsSymptom rates were higher among females, Black people, and those 40 years and older or with pre-existing conditions.
Baca lebih lajut »
Covid-19: NI records five Covid-linked deaths, 889 casesThe total number of deaths linked to coronavirus in NI since the start of the pandemic is 2,504
Baca lebih lajut »
U.S. and EU struggle with the same question: How to maximize COVID-19 vaccinationsDespite apparently divergent strategies, officials in both the U.S. and the EU are struggling with the same question: how to boost vaccination rates to the max and end a pandemic that has repeatedly thwarted efforts to control it.
Baca lebih lajut »